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Accepted 25 November 2013; Published online 28 February 2014AbstractBackground: Lack of standardization of outcome measures limits the usefulness of clinical trial evidence to inform health care deci-
sions. This can be addressed by agreeing on a minimum core set of outcome measures per health condition, containing measures relevant to
patients and decision makers. Since 1992, the Outcome Measures in Rheumatology (OMERACT) consensus initiative has successfully
developed core sets for many rheumatologic conditions, actively involving patients since 2002. Its expanding scope required an explicit
formulation of its underlying conceptual framework and process.
Methods: Literature searches and iterative consensus process (surveys and group meetings) of stakeholders including patients, health
professionals, and methodologists within and outside rheumatology.
Results: To comprehensively sample patient-centered and intervention-specific outcomes, a framework emerged that comprises three
core ‘‘Areas,’’ namely Death, Life Impact, and Pathophysiological Manifestations; and one strongly recommended Resource Use. Through
literature review and consensus process, core set development for any specific health condition starts by identifying at least one core
‘‘Domain’’ within each of the Areas to formulate the ‘‘Core Domain Set.’’ Next, at least one applicable measurement instrument for each
core Domain is identified to formulate a ‘‘Core Outcome Measurement Set.’’ Each instrument must prove to be truthful (valid),* This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
This article presents the main arguments and supporting information on
the development of OMERACT Filter 2.0. Further details are provided in a
series of publications in the Proceedings of the OMERACT 11 conference,
in press at the Journal of Rheumatology. These will be made freely avail-
able (see www.omeract.org).
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746 M. Boers et al. / Journal of Clinical Epidemiology 67 (2014) 745e753discriminative, and feasible. In 2012, 96% of the voting participants (n5 125) at the OMERACT 11 consensus conference endorsed this
model and process.
Conclusion: The OMERACT Filter 2.0 explicitly describes a comprehensive conceptual framework and a recommended process to
develop core outcome measurement sets for rheumatology likely to be useful as a template in other areas of health care.  2014 The
Authors. Published by Elsevier Inc.
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1. Introduction documenting the validity of selected instruments by applying
Open access under CC BY-NC-ND license. Randomized controlled trials (RCTs) are performed to
compare benefits and harms between interventions. To
inform health care decisions, outcome measures relevant
to patients and decision makers must be included and re-
ported [1].
Disagreement on the choice of outcome measures has re-
sulted in inconsistent reporting, potential for reporting bias,
and reduced quality of guidelines depending on such trial
results [2,3]. Recent examples include chronic obstructive
pulmonary disease [4], diabetes mellitus [5], and surgical
oncology [6]. The Patient-Centered Outcomes Research
Institute (PCORI) was established by the US Congress to
improve the quality of information for health care decisions.
It recommends ‘‘measuring outcomes that people in the pop-
ulation of interest notice and care about’’ [7].Within rheuma-
tology, the Outcome Measures in Rheumatology initiative
(OMERACT) has successfully worked since 1992 to improve
outcome measurement for many rheumatologic conditions
[8], including rheumatoid arthritis [9], ankylosing spondylitis
[10], and osteoarthritis [11]. It has done so by developing
widely endorsed ‘‘core outcome measurement sets,’’ each a
minimum set of outcome measures that must be reported in
all RCTs in a given health condition. Reporting consistency
is ensured when investigators always report the results of
the core set measures, regardless of the primary purpose of
the trial. The core sets by nomeans limit investigators in their
choice of primary or other outcome measures of interest.
Core sets have also been developed in other health areas.
Their development most frequently started with a literature
review of trials to date for consideration by an expert panel
of health care professionals [12]. Relevant domains for
assessment were then selected, often through ranking, and
sometimes including suggestions for instruments to mea-
sure these domains, to form the proposed core set [12].
Criticisms of such an approach include: first, that it does
not include a systematic survey of stakeholders, especially
patients; second, that it is not explicitly linked to a concep-
tual framework describing the concepts to be measured;
and third, that instrument selection is not based on system-
atic evidence of their measurement properties. Thus, these
core sets may omit important concepts (either overlooked
or lost in the selection process) and recommend suboptimal
instruments.
In contrast, the OMERACT consensus process is
grounded in a framework first formulated by Fries et al.
[13] and expanded by Kirwan [14], and a process ofthe ‘‘OMERACT Filter’’ to each candidate instrument
(Table 1) [15]. The Filter was published in 1998 and summa-
rizes key instrument properties (validity, reliability and
responsiveness, and usability) in three plain language words,
namely Truth, Discrimination, and Feasibility. In addition, an
expanding group of patients with a rheumatic condition have
been selected and trained in measurement. They have partic-
ipated in OMERACT conferences and working groups since
2002 to identify important domains and to ensure that these
are appropriately addressed.
The OMERACT community has grown in membership
and in number of conditions covered, making clarification
and optimization of its framework and process necessary.
This includes the distinction between potential domains
(‘‘what to measure’’) and measurement instruments
(‘‘how to measure’’); and the process to identify these
and to reach consensus on which to include in a core set,
procedures implicit in its earlier work but not overtly
defined or described. OMERACT feels such work might
also be of use in other areas of health care, for example
in the recent ‘‘Core Outcome Measures in Effectiveness
Trials’’ (COMET) initiative, which aims to convene core
set developers across all disease areas [16].
This article describes the upgrade of the OMERACT
framework and the process of development of core outcome
measurement sets in rheumatology, collectively termed
‘‘OMERACT Filter 2.0.’’ We believe that this framework
and process will be useful as a template for development
of core sets in other subspecialties.2. Methods
Asystematic literature reviewwas performed to describe the
process bywhich available conceptual frameworks (ormodels)
of health, disease, anddisability arose,with a goal to informand
improve the implicit OMERACT framework [12e14]. From
the review, it became apparent that other existing frameworks
were not focused on measurement in studies of efficacy and
effectiveness, and that their development process was in-
sufficiently documented. As a consequence, the OMERACT
executive decided to build a generic model of core set
development around its own framework aimed at RCTs and
longitudinal observational studies for endorsement by the
OMERACT community.
Definitions of key concepts were collected from the
literature and operationalized, or developed de novo.
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 The conceptual framework encompasses the com-
plete content of what is measureable in a trial,
including both patient-centered and intervention-
specific information.
 The framework comprises three core ‘Areas’:
Death, Life Impact and Pathophysiologic Manifes-
tations; and one strongly recommended: Resource
Use.
 Core set development for any specific health condi-
tion starts by identifying at least one core ‘Domain’
within each of the Areas to formulate the ‘Core
Domain Set’.
 Next, at least one applicable measurement instru-
ment for each core Domain is identified to formu-
late a ‘Core Outcome Measurement Set’.
 For applicability, each instrument must prove to be
truthful (valid), discriminative, and feasible.Within the Cochrane Collaboration, experts helped develop
and gave feedback on subsequent drafts by way of a tar-
geted survey supplemented with open comments. A total
of 18 of these experts met at the second COMET confer-
ence in July 2011 for further discussions. Next, an exten-
sive internet-based survey was conducted with three
groups, namely COMET-2 participants, participants of the
current and previous OMERACT conferences including pa-
tient experts, and subscribers to the Evidence-Based Health
Listserv [17].
At the same time, a proposal for specification of the
OMERACT process to develop core outcome measurementTable 1. The original OMERACT Filter to determine applicability
of a measurement instrument in a setting [15]
Truth
Is the measure truthful, does it measure what is intended?
Is the result unbiased and relevant? The word ‘‘truth’’ captures
issues of face, content, and construct validity (As gold standards
are often not available, criterion validity is mostly not tested).
Discrimination
Does the measure discriminate between situations of interest?
The situations can be states at one time (for classification or
prognosis) or states at different times (to measure change).
The word ‘‘discrimination’’ captures issues of reliability and
sensitivity to change.
Feasibility
Can the measure be applied easily, given constraints of time,
money, and interpretability?
The word ‘‘feasibility’’ captures an essential element in the
selection of measures, one that may be decisive in determining a
measure’s success.
Abbreviation: OMERACT, Outcome Measures in Rheumatology.sets was circulated to all active working groups (n5 20)
within OMERACT and adapted after feedback. Finally, at
the OMERACT 11 conference in May 2012 in Pinehurst,
NC, a presentation of the draft conceptual framework and
the development process for core sets (collectively termed
‘‘OMERACT Filter 2.0’’) was discussed in five interactive
sessions that combined plenary and small group discussions.
Based on all feedback received, the final proposal was
presented and voted on in the closing session. Attendees
included clinicianeresearchers (58%), full researchers
(11%), industry researchers (13%), patient experts (9%),
and statisticians (3%). Of note, several of the researchers pre-
sent at OMERACT and several members of the OMERACT
executive have expertise in health economics.3. Results
After several iterations, the initial draft proposal was
provided as prereading material for 2,293 participants ap-
proached for the internet survey (1,484 Evidence Based
Health listserv participants; 131 COMET 2 participants;
and 678 OMERACT previous and current conference dele-
gates) [18]. A total of 262 survey responses were received
(11%), with wide support for the draft model and sugges-
tions for improvement and clarification. Many responses
raised similar issues, and new suggestions were not found
in the final set of returns, suggesting saturation of informa-
tion. Detailed discussions at OMERACT contributed
further clarifications [19e23]. Of 125 voting participants,
120 (96%) endorsed the final proposal, which we describe
in the following sections [24].
The first part of Filter 2.0, the framework, is designed to
ensure comprehensiveness (content validity) of the core set
by specifying all key aspects, to be termed ‘‘Areas,’’ of a
health condition (Fig. 1): three Areas that describe the
‘‘Impact of Health Conditions,’’ specifically Death, Life
Impact, and Resource Use; and the fourth Area that de-
scribes Pathophysiological manifestations. We posit that
these Areas encompass the complete content of what is
measureable in a trial, including both patient-centered
and intervention-specific information. The OMERACT 11
participants endorsed that all Areas except Resource Use
should always be addressed in clinical trials. The Areas,
further described in the following sections, can be likened
to large ‘‘containers’’ for the concepts of interest, herein
termed Domains and Subdomains.
The second part is the process of core set development.
To decide what to measure, (Sub)Domains will need to be
specified within each Area to create the Core Domain Set.
Once this step is complete, the question on how to measure
can be answered by deciding on the specific measurement
instruments for each (Sub)Domain to create the Core
Outcome Measurement Set. Thus, a core set specifies at
least one Domain in each Area and at least one valid instru-
ment in each Domain. This is described further in process
Fig. 1. Conceptual framework of Core Areas for outcomemeasurement in the setting of health intervention studies. Resource Use has a lighter shade
to indicate it is currently strongly recommended, but not mandatory for inclusion. The choice of specific Domains within an Area depends on the
context for which the core set is being developed in all areas, domains can be generic or made more specific, for example disease-specific, time-spe-
cific (eg, short or long-term), specific for patient preference, and so forth. ICF, International Classification of Functioning, Disability and Health.
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tions of key concepts are listed in Table 2.
It is important to stress that a core set in no way limits
the choice of primary and secondary outcomes in a partic-
ular trial. The core set describes the minimum set of Do-
mains and Instruments to be measured in each of the
Areas, which may already coincide with the primary or sec-
ondary outcomes of interest in that trial. If not, the investi-
gator will have to include additional outcomes to comply
with requirements of the core set.4. The framework in further detail
4.1. Impact of health conditions
This includes all aspects of health or a health condition
that are important to the patient and society. Impact is split
into three Areas, namely Death, Life Impact, and Resource
Use. In all Areas of Impact, there are various possibilities
for further specification into ‘‘Domains’’ (and if useful into
‘‘Subdomains’’); this will be determined by the condition
and setting or scope for which the core set is being devel-
oped. Some suggestions for Domain specification are
described in the following sections.
Under Death, possible specifications include generic and
disease-specific, that is, all cause vs. disease-specificmortality; and intervention-specific (eg, death owing to sur-
gery or transplantation). In conditions where death rarely oc-
curs during a trial, this area could be covered in the core set by
requiring a simple report of any deaths (or their lack), which
is already a standard requirement in current guidelines.
Under Life Impact, OMERACT strongly suggests that
core set developers consider both the domains of the Interna-
tional Classification of Functioning, Disability and Health
(ICF) [25] and domains within the concept of health-
related quality of life, for example, as elaborated by Wilson
and Cleary’s model [26]. The alignment of our Framework
with ICF Domains and health-related quality of life is shown
in Table 3. In trials primarily focused on understanding a
mechanism of action or proof of concept, the core set will
describe the minimum to be measured under Life Impact.
Resource Use describes the economic impact of health
conditions both on society and on the individual. Both the
presence of a health condition and its treatment incur
resource use. In the development of health interventions,
early consideration of resource use has become essential,
as increasing health care costs present challenges for even
the richest nations [27]. In low-income countries, the avail-
ability of an intervention and patient access to it may be
determined by its associated resource use.
The OMERACT strongly recommends the inclusion of
at least one Domain describing Resource Use, but it need
Table 2. Definitions of key concepts
Health
A state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity (WHO, 1948).
Discussions are ongoing because this definition has many disadvantages, but it has not yet been replaced.
Health Condition
A situation of impaired health.
Health Intervention
An activity performed by, for, with or on behalf of a client(s) whose purpose is to improve individual or population health,
to alter or diagnose the course of a health condition, or to improve functioning.
(Draft WHO definition; ‘by’ added)
Core Area
An aspect of health or a health condition that needs to be measured to appropriately assess the effects of a health intervention.
Core Areas are broad concepts consisting of a number of more specific concepts called Domains.
(Sub)Domain
Component of Core Area: a concept to be measured, a further specification of an aspect of health, categorized within a Core Area.
Outcome
Any identified result in a (Sub)Domain arising from exposure to a causal factor or a health intervention.
(Adapted from John Last, Dictionary of Epidemiology. Toronto: Oxford Press 1995)
Generic word that has been used with different definitions; has often been used interchangeably with ‘‘Outcome Measure’’ and ‘‘Endpoint.’’
Measurement Instrument
A tool to measure a quality or quantity of a variable, in this context a (Sub)Domain or a contextual factor.
The tool can be a single question, a questionnaire, a score obtained through physical examination, a laboratory measurement, a score obtained
through observation of an image, and so on.
Outcome Measurement Instrument
A measurement instrument chosen to assess Outcome.
The result of measurement (recently termed ‘specific metric’ [33]) can be expressed as change, as end result, as cumulative result, or as or as
‘‘time to event’’ in a (Sub)Domain.
Example: in pain measurement, the instrument could be a visual analog scale, and outcome could be an improvement on that scale (ie, change,
an end-of study pain score, the achievement of an acceptable pain state (both, end result); or the area under the curve of pain scores during the
study (cumulative result).
Core Domain Set
For studies of health interventions, the minimum set of Domains and Subdomains necessary to adequately cover all Core Areas, that is,
adequately measure all relevant concepts of a specific health condition within a specified setting. Describes what to measure.
Currently, the COMET initiative uses the term ‘‘Core Outcome Set’’ for this concept. OMERACT has decided not to adopt this term, as there is no
consensus on its technical definition
Core Outcome Measurement Set
The minimum set of outcome measurement instruments that must be administered in each intervention study of a certain health condition within
a specified setting to adequately cover a corresponding Core Domain Set. Describes how to measure.
Within OMERACT, we have chosen to not to use the word ‘‘endpoint,’’ and use the word Outcome only in the context of the Core Outcome
Measurement Set.
Setting (Scope)
The set of factors that describes the studies and circumstances to which the core outcome measurement set will apply.
This is determined by the study questions and includes the health condition(s), target population, interventions, and so on.
Contextual Factor
Variable that is not an outcome of the study, but needs to be recognized (and measured) to understand the study results.
This includes potential confounders and effect modifiers.
Abbreviation: OMERACT, Outcome Measures in Rheumatology.
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intervention, the measurement of resource use could be
limited to listing the number of procedures and clinic visits
necessary when this intervention is introduced in routine
care. As more experience is gained, this Area may be
changed from strongly recommended to Core and thus be
addressed in all trials.
4.2. Pathophysiological manifestations of health
conditions
In addition to Impact, OMERACT feels that in trials,
measurement of pathophysiological manifestations is essen-
tial to assess whether or not the effect of the intervention spe-
cifically targets the pathophysiology of the health condition.Pathophysiology can include psychosocial manifestations.
Example Domains include: organ function (eg, renal func-
tion), reversible manifestations (including modifiable risk
factors and actual manifestations of ill health), and irrevers-
ible manifestations (including unmodifiable risk factors and
damage). This Area also encompasses all biomarkers and
surrogate outcomes. In trials primarily focused on Impact,
the core set will describe the minimum to be measured under
pathophysiological manifestations.
4.3. Additional concepts and considerations
4.3.1. Adverse events
Benefit and harm can be regarded as opposite directions
on one ‘‘impact scale,’’ measurable in one of the core
Table 3. Comparison of OMERACT Framework to a model of Health-related Quality of Life [26] and the International Classification of Functioning,
Disability and Health (ICF) [25]
OMERACT framework core areas/concepts Health-Related quality of life model ICF
Death
Pathophysiological manifestations Biological and physiological variables Body function and structure
Life impact Symptom status Activity
Functional status
General health perceptions Participation
Overall quality of life
Contextual factors/scope Characteristics of the individual Contextual factors
Characteristics of the environment
Nonmedical factors
Health condition/scope Health condition
Abbreviations: OMERACT, Outcome Measures in Rheumatology; ICF, International Classification of Functioning, Disability and Health.
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(adverse effects) as carefully as benefit. Thus, OMERACT
endorses that adverse events continue to be labeled or
flagged to allow separate assessment of anticipated benefit
and potential harm.
4.3.2. Setting and contextual factors
Core set developers need to specify the setting of the
core set, and consider if any contextual factors need to be
documented in every trial. Setting (or scope) includes the
health condition, target population for the intervention, type
of intervention, and so on. Contextual factors can be
defined as those that are not the primary object of research
but that may influence the results or the interpretation of the
results. These include potential confounders and effect
modifiers (most of which should be eliminated by random-
ization), as well as factors that define the generalizability ofFig. 2. Development of a Core Domain Set from the Core Areas of measurem
Subdomains necessary to adequately cover all Core Areas, that is, fully mea
ified setting.the study findings. One way of representing the interaction
between contextual factors and other measured aspects of
the impact of a health condition has been illustrated by
the so-called ‘‘impact triad’’ [28].5. Developing a Core Outcome Measurement Set:
process suggestions
OMERACT suggests a stepwise approach to core set
development (Figs. 2 and 3). The first step is defining the
setting of the core set and deciding which (if any) contex-
tual factors need to be measured alongside the outcome
measures. Developers must also decide whether specific
adverse events need to be monitored as part of the core set.
The next step is determining what to measure (Fig. 2),
starting with a literature search to document all (sub)do-
mains and instruments used to date. At the same time,ent. A Core Domain Set is defined as the minimum set of Domains and
sure all relevant concepts of a specific health condition within a spec-
Fig. 3. Development of a Core Outcome Measurement Set from a Core Domain Set. The Core Outcome Measurement Set is defined as: the min-
imum set of outcome measurement instruments that must be administered in each intervention study of a certain health condition within a spec-
ified setting to adequately cover a corresponding Core Domain Set. As depicted, the development process allows core set developers to declare a
Preliminary Core Outcome Measurement Set when not all Domains are covered by at least one applicable measurement instrument.
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what each stakeholder group deems essential to measure.
During this process, developers refer to the framework
and match the input to specific Domains and Subdomains
in each Core Area relevant to the chosen setting. To ensure
face and content validity, explicit input from all stake-
holders, including patients, is essential to identify relevant
(sub)domains and to expose gaps in what has been
measured to date [29]. The end result of this process is
a draft subjected to a consensus procedure with all stake-
holders, resulting in a Core Domain Set. Core Domains in
the Areas of Death, Life Impact, and Resource Use can be
equated with the ‘‘critical outcomes’’ of the Grading of
Recommendations Assessment, Development and Evalua-
tion (GRADE) system [30]. To do more justice to the
value of all the domains and instruments reviewed, these
can be viewed as occupying a series of concentric spheres:
the core domains in the middle, surrounded by domains of
decreasing importance [11].
The final step is deciding how to measure the selected
Core Domains (Fig. 3). The literature review provides a list
of available measurement instruments; where no instru-
ments are available in a (sub)domain, these need to be
developed. Each instrument is then studied to document
its applicability in the chosen setting (Table 1) [15]. Draw-
ing on key developments that have occurred after the
formulation of the first Filter such as the work by the COS-
MIN group [31,32], and the GRADE recommendations
[30], OMERACT is developing specific guidelines on the
procedures to document applicability of instruments.When all Core Domains can be measured by at least one
applicable instrument, the end result is a draft that again is sub-
jected to a consensus procedurewith all stakeholders, resulting
in the Core Outcome Instrument Set. Where core contextual
factors and adverse events have been specified, instruments
tomeasure thesemust also pass theOMERACTFilter. Formu-
lation of a ‘‘preliminary’’ CoreOutcomeMeasurement Set can
be useful in situations where one or more Domains were
incompletely coveredbyapplicablemeasurement instruments.6. Discussion
OMERACT has been active in the field of outcome mea-
surement in rheumatology since 1992. It has now upgraded
and clarified its working process for developing core
outcome sets in two ways. First, it has formulated a novel
conceptual framework of measurement of health conditions
in the setting of health interventions. The Core Areas do not
describe novel concepts, but their explicit juxtaposition in
the framework is novel; in this way they ensure content val-
idity across patient-important and intervention-specific in-
formation. In its overarching concept of ‘‘Impact,’’ the
framework confirms that assessment of patient-centered
outcomes in trials is essential to inform health care deci-
sions, as suggested by the PCORI [1]. Second, OMERACT
has made the process of subsequent outcome development
explicit by agreeing on the definitions of key concepts,
including that of a Core Domain Set that logically must
be developed before a Core Outcome Measurement Set.
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and measurement instruments that will be consistent with
the reporting framework recently developed for the US
Clinical Trial Registry [33]. The registry additionally de-
fines the term ‘‘specific metric’’ for the expression of the
measurement result in a study (eg, as change score or as
end score), and ‘‘method of aggregation’’ for the way the
measurement result is summarized for the patients in each
treatment group (eg, as mean and standard deviation).
During the development of this framework and process,
now collectively termed ‘‘OMERACT Filter 2.0,’’ we
sought to be maximally inclusive by engaging as many
stakeholders as possible. OMERACT has recognized the
patient perspective since its initiation [34] and included pa-
tients educated in measurement methodology in its working
process since 2002 [35].
Energized by the enthusiastic reception and feedback
received from participants of the COMET conference, we
strove to make the framework as generic as possible so that
it could be applied in other disease areas. Consequently, it in-
corporates considerable input from professionals working in
other medical specialties. Our survey intended to reach out
to a wide audience but many of the people approached (espe-
cially from theEvidenceBasedHealthListserv [17]) chose not
to respond. This is a common experience with internet-based
surveys, in this case probably caused both by lack of interest
and the burden of the task. At this stage of development, we
suggest that the quality and saturation of information is more
important than a high response rate. Nevertheless, the frame-
work is grounded in the setting of chronic diseases, and more
specifically, rheumatology; the low overall response rate to the
survey precludes conclusions on the acceptability of the
framework in the wider scientific community. At present, the
framework has face validity through its development process
and the high degree of consensus obtained. This will need to
be complemented by evidence of applicability in use. As such,
the term ‘‘Filter 2.0’’ indicates the possibility of iterativemodi-
fication over time as experience with its application expands
and gaps and/or redundancies are identified. The next step is
the development of an OMERACT Handbook with updated
and explicit working methods to select and assess the quality
ofmeasurement instruments thatwill populate a core outcome
measurement set.
In conclusion, OMERACT has established a strongly
endorsed, comprehensive framework and process for devel-
oping core outcome measurement sets, which has been
fruitful within rheumatology. We hope that OMERACT Fil-
ter 2.0 will serve a more generic function, and be applied in
the development of core outcome measurement sets for
many health conditions.Acknowledgments
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